Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced plans to open three new Allergan Medical Institute (AMI) Training Centers in the United States. The centers will be located in Irvine, California, Atlanta, and Austin, with the first facility opening in 2025 at the company's headquarters in Orange County.
The training centers will provide comprehensive education programs for licensed aesthetics providers, focusing on clinical techniques, complications management, and business operations. Led by AMI Medical Director Dr. Saami Khalifian, the facilities will offer hands-on curriculum and learning experiences for providers at all experience levels.
The initiative expands AMI's global presence to more than ten locations worldwide. In November 2024, the company launched AMI Business Education on their online platform, offering free business operations courses to practitioners.
Allergan Aesthetics, una società di AbbVie (NYSE: ABBV), ha annunciato piani per aprire tre nuovi Centri di Formazione dell'Allergan Medical Institute (AMI)
I centri di formazione offriranno programmi educativi completi per i fornitori di estetica autorizzati, concentrandosi su tecniche cliniche, gestione delle complicazioni e operazioni aziendali. Guidati dal Direttore Medico dell'AMI, il Dr. Saami Khalifian, le strutture offriranno un curriculum pratico e esperienze di apprendimento per fornitori di tutti i livelli di esperienza.
Questa iniziativa espande la presenza globale dell'AMI a più di dieci sedi in tutto il mondo. Nel novembre 2024, l'azienda ha lanciato l'AMI Business Education sulla propria piattaforma online, offrendo corsi gratuiti sulle operazioni aziendali ai professionisti.
Allergan Aesthetics, una empresa de AbbVie (NYSE: ABBV), anunció planes para abrir tres nuevos Centros de Capacitación del Allergan Medical Institute (AMI) en los Estados Unidos. Los centros estarán ubicados en Irvine, California, Atlanta y Austin, con la primera instalación inaugurándose en 2025 en la sede de la empresa en el Condado de Orange.
Los centros de capacitación ofrecerán programas educativos integrales para proveedores de estética licenciados, enfocándose en técnicas clínicas, manejo de complicaciones y operaciones comerciales. Liderados por el Director Médico de AMI, el Dr. Saami Khalifian, las instalaciones ofrecerán un currículo práctico y experiencias de aprendizaje para proveedores de todos los niveles de experiencia.
La iniciativa expande la presencia global de AMI a más de diez ubicaciones en todo el mundo. En noviembre de 2024, la empresa lanzó AMI Business Education en su plataforma en línea, ofreciendo cursos gratuitos sobre operaciones comerciales a los profesionales.
알러간 미학은 AbbVie(뉴욕증권거래소: ABBV) 소속 회사로, 미국에 새로운 알러간 의료 연구소(AMI) 교육 센터를 세 곳 열 계획을 발표했습니다. 센터는 캘리포니아주 어바인, 애틀랜타, 오스틴에 위치하며, 첫 번째 시설은 2025년에 오렌지 카운티에 있는 회사 본사에서 개장할 예정입니다.
교육 센터는 면허가 있는 미학 제공자를 위한 포괄적인 교육 프로그램을 제공하며, 임상 기술, 합병증 관리 및 비즈니스 운영에 중점을 둡니다. AMI 의료 이사인 사미 칼리피안 박사가 이끄는 이 시설은 모든 경험 수준의 제공자를 위한 실습 커리큘럼과 학습 경험을 제공합니다.
이 이니셔티브는 AMI의 글로벌 존재를 전 세계 10개 이상의 위치로 확장합니다. 2024년 11월, 회사는 온라인 플랫폼에서 AMI 비즈니스 교육을 시작하여 전문가에게 무료 비즈니스 운영 과정을 제공합니다.
Allergan Aesthetics, une entreprise d'AbbVie (NYSE: ABBV), a annoncé son intention d'ouvrir trois nouveaux Centres de Formation de l'Allergan Medical Institute (AMI) aux États-Unis. Les centres seront situés à Irvine, Californie, Atlanta et Austin, avec la première installation qui ouvrira en 2025 au siège de l'entreprise dans le comté d'Orange.
Les centres de formation offriront des programmes éducatifs complets pour les prestataires d'esthétique agréés, en mettant l'accent sur les techniques cliniques, la gestion des complications et les opérations commerciales. Dirigées par le Dr Saami Khalifian, directeur médical de l'AMI, les installations proposeront un curriculum pratique et des expériences d'apprentissage pour les prestataires de tous niveaux d'expérience.
Cette initiative élargit la présence mondiale de l'AMI à plus de dix emplacements dans le monde entier. En novembre 2024, l'entreprise a lancé l'AMI Business Education sur sa plateforme en ligne, offrant des cours gratuits sur les opérations commerciales aux praticiens.
Allergan Aesthetics, ein Unternehmen von AbbVie (NYSE: ABBV), hat Pläne angekündigt, drei neue Allergan Medical Institute (AMI) Schulungszentren in den Vereinigten Staaten zu eröffnen. Die Zentren werden in Irvine, Kalifornien, Atlanta und Austin angesiedelt sein, wobei die erste Einrichtung 2025 am Unternehmenssitz im Orange County eröffnet wird.
Die Schulungszentren bieten umfassende Bildungsprogramme für lizenzierte ästhetische Anbieter an, die sich auf klinische Techniken, das Management von Komplikationen und Geschäftsabläufe konzentrieren. Unter der Leitung von Dr. Saami Khalifian, dem medizinischen Direktor von AMI, werden die Einrichtungen praxisnahe Lehrpläne und Lernerfahrungen für Anbieter aller Erfahrungsstufen anbieten.
Die Initiative erweitert die globale Präsenz von AMI auf mehr als zehn Standorte weltweit. Im November 2024 startete das Unternehmen AMI Business Education auf seiner Online-Plattform und bietet kostenlosen Unterricht zu Geschäftsabläufen für Fachleute an.
- Expansion of training infrastructure with three new U.S. centers strengthens market position
- Global presence increased to over 10 training locations worldwide
- Addition of free business education courses enhances value proposition for practitioners
- None.
Insights
This strategic expansion of AMI training centers represents a sophisticated move to strengthen AbbVie's competitive moat in the aesthetics market through education-based differentiation. The establishment of three new state-of-the-art facilities creates multiple strategic advantages:
- Provider Loyalty Enhancement: By offering comprehensive training programs spanning clinical skills to business operations, Allergan Aesthetics is positioning itself as an indispensable partner for aesthetic practitioners. This educational ecosystem creates strong switching costs, as providers become deeply integrated with Allergan's protocols and products.
- Market Share Protection: The training centers serve as a powerful defensive mechanism against competing products, particularly in the neurotoxin and dermal filler segments. By training providers on Allergan's portfolio, the company ensures continued preference for their products over emerging alternatives.
- Revenue Acceleration Catalyst: The strategic placement of centers in key markets (Orange County, Atlanta, and Austin) targets regions with high concentrations of aesthetic practices and growing demand. This geographical strategy optimizes market penetration and creates regional centers of excellence that can influence broader adoption.
The integration of business education through the AMI online platform is particularly noteworthy, as it helps practices optimize operations and growth - creating a virtuous cycle of increased product utilization and practice success. This comprehensive approach to provider support extends beyond traditional product training, establishing Allergan Aesthetics as a important partner in practice development.
The global expansion to over ten training centers demonstrates AbbVie's commitment to scaling this educational infrastructure, which serves as both a competitive differentiator and a barrier to entry for emerging competitors. This investment in education infrastructure is likely to yield long-term returns through sustained market leadership and enhanced provider loyalty in the growing aesthetics market.
- Allergan Medical Institute (AMI) Training Centers to offer most comprehensive, training programs accelerating providers' consultative and clinical skills
- Innovative curriculum will empower providers to deliver outcomes with excellence and support loyal patient relationships
"The new AMI Training Centers are designed to help expand and elevate our existing best-in-class training programs," said Glen Curran, Senior Vice President,
Since its first aesthetic approval for BOTOX® Cosmetic (onabotulinumtoxinA), Allergan Aesthetics has led the industry, ensuring excellence in training to empower aesthetic providers to deliver safe, natural-looking results for their patients. AMI is committed to elevating the science and art of aesthetics through high-impact educational programs to aesthetic providers that enable them to advance their capabilities. With the new
DRIVING INNOVATION IN TRAINING
The new AMI Training Centers, strategically built in key markets, will leverage top innovations in products, clinical education, techniques, and technologies to drive continued growth and progress across the aesthetic market. The offerings are focused on delivering safe and desirable patient outcomes and helping aesthetic practices to create lasting business success for themselves through patient acquisition and satisfaction.
The Centers will feature AMI faculty trainers offering engaging hands-on curriculum and an unparalleled learning experience for providers and business managers, regardless of where they are in their learning journey. The AMI Training Centers, presided over by AMI Medical Director Dr. Saami Khalifian, are designed to enhance the clinical techniques, complications management expertise, and business acumen of participants. Trainees will gain the tools, skills, and confidence needed to continue their journey as aesthetic professionals, while building a community of mentors and peers to help foster ongoing success.
"I've been actively involved in bringing these training centers to life—working closely to develop innovative solutions, refine ideas, and guide these concepts from vision to reality. It's an honor to offer such a groundbreaking training experience to professionals nationwide," said Dr. Saami Khalifian, Double Board-Certified Dermatologist and Medical Director AMI Training Centers. "Allergan Aesthetics leads the industry in medical education by continually investing in robust programs that set a new standard for excellence. These Centers exemplify that commitment in ways unlike anything providers have seen before. My hope is that every participant leaves feeling empowered, equipped, and inspired to reach their highest potential faster than they ever thought possible."
CONTINUED EXCELLENCE IN EDUCATION
Developed in partnership between Allergan Aesthetics and expert healthcare professionals, programming is high-caliber and intended to advance scientific knowledge and technical skills in a variety of formats including hands-on training, roundtable forums, national symposia, live webcast events, exclusive resources, and a robust online learning program, AMI online.
In November 2024, Allergan Aesthetics launched AMI Business Education to the AMI online learning platform to provide free courses to practitioners with business operations education.
The first training center, AMI Orange County, located at Allergan Aesthetics Headquarters in
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.AllerganAesthetics.com.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
About Allergan Medical Institute (AMI)
AMI is the training arm of Allergan Aesthetics, delivering on its commitment to excellence in aesthetics education. AMI empowers aesthetics providers and business owners with innovative training offerings across Allergan Aesthetics robust portfolio of products to maximize educational impact and elevate the standard of exemplary patient experiences. For more information visit https://us.allerganmedicalinstitute.com/us/en/splash-page.html.
About AMI Online
AMI Online is a comprehensive learning platform featuring in-depth education and training on the Allergan Aesthetics Portfolio of Products available on demand, 24/7. It is designed to provide an adaptable, personalized learning experience that helps injectors of all levels further their knowledge, refine their skills, and advance their expertise. AMI Online enables injectors and their staff to review injection techniques, test their knowledge, earn certificates, and stay up to date with upcoming educational events. Allergan Medical Institute® Faculty offer expert training through engaging, personalized content available to all AMI Online members for free.
BOTOX® Cosmetic (onabotulinumtoxinA) Indications and Important Safety Information
Indications
BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of:
- Moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity
- Moderate to severe lateral canthal lines associated with orbicularis oculi activity
- Moderate to severe forehead lines associated with frontalis activity
- Moderate to severe platysma bands associated with platysma muscle activity
SAFETY CONSIDERATIONS
WARNING: DISTANT SPREAD OF TOXIN EFFECT
Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses. |
CONTRAINDICATIONS
BOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.
WARNINGS AND PRECAUTIONS
Seek immediate medical attention if respiratory, speech, or swallowing difficulties occur. The potency Units of BOTOX® Cosmetic are not equivalent to other preparations of botulinum toxin products. Potential serious adverse reactions have been reported after BOTOX® Cosmetic injections for unapproved uses. Concomitant neuromuscular disorder may exacerbate clinical effects of treatment. Use with caution in patients with compromised respiratory function.
DRUG INTERACTIONS
Patients receiving concomitant treatment of BOTOX® Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like agents), or muscle relaxants, should be observed closely because the effect of BOTOX® Cosmetic may be potentiated.
USE IN SPECIFIC POPULATIONS
There are no studies or adequate data from postmarketing surveillance on the developmental risk associated with use of BOTOX® Cosmetic in pregnant women.
Please see full Prescribing Information including Boxed Warning and Medication Guide.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Ember Garrett
Communications and Public Relations
garrett_ember@allergan.com
Kate McShane
Corporate Communications
Kate.mcshane@allergan.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/allergan-aesthetics-to-launch-three-new-state-of-the-art-training-centers-in-the-us-expanding-access-to-high-quality-aesthetics-training-302374118.html
SOURCE AbbVie
FAQ
When will ABBV open its first new AMI Training Center in the US?
How many AMI Training Centers will ABBV operate globally after the US expansion?
What locations did ABBV choose for the new AMI Training Centers?
When did ABBV launch the AMI Business Education platform?
Who is leading ABBV's new AMI Training Centers as Medical Director?
